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Abstract 
The cooking of meat results in the generation of heterocyclic amines (HCA), 
the most abundant of which is 2-amino-1-methyl-6-phenylimidazo[4,5-
b]pyridine (PhIP). Data from epidemiological, mechanistic, and animal studies 
indicate that PhIP could be causally linked to breast cancer incidence. 
Besides the established DNA damaging and mutagenic activities of PhIP, the 
chemical is reported to have oestrogenic activity that could contribute to its 
tissue specific carcinogenicity. In this study we investigated the effect of 
treatment with PhIP and 17-β-estradiol (E2) on global microRNA (miRNA) 
expression of the oestrogen responsive MCF-7 human breast 
adenocarcinoma cell line. 
 
PhIP and E2 caused widespread and largely over-lapping effects on miRNA 
expression, with many of the commonly affected miRNA reported to be 
regulated by oestrogen and have been implicated in the initiation and 
progression of breast cancer. The regulatory activity of the miRNAs we show 
here to be responsive to PhIP treatment, are also predicted to mediate cellular 
phenotypes that are associated with PhIP exposure. Consequently, this study 
offers further support to the ability of PhIP to induce widespread effects via 
activation of oestrogen receptor alpha (ERα). Moreover, this study indicates 
that deregulation of miRNA by PhIP could potentially be an important non-
DNA-damaging carcinogenic mechanism in breast cancer. 
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Introduction 
 
The cooking of meat results in the formation of heterocyclic amines (HCA), 
with the most abundant one being 2-amino-1-methyl-6-phenylimidazo[4,5-
b]pyridine (PhIP) (Felton et al., 1986; Murray et al., 1993). In animal studies 
PhIP has been shown to increase the incidence of mammary and colon 
cancers (Ito et al., 1991). Consequently, it has been postulated that exposure 
of humans to HCA such as PhIP through their diet could be a major 
determinant of breast cancer incidence. Epidemiological studies examining 
the potential association of PhIP with the incidence of human breast cancer 
have given inconsistent results, with some studies suggesting increased risk 
(Sinha et al., 2000; Steck et al., 2007; Taylor et al., 2007) while others found 
no association (Delfino et al., 2000; Kabat et al., 2009). Elucidating the 
mechanisms by which PhIP can drive breast carcinogenesis would greatly 
facilitate the assessment and management of risk to exposed human 
populations. 
 
PhIP is primarily metabolised through the action of CYP1A2 to the N-hydroxy 
derivative (Zhao et al., 1994). This metabolite is then esterified to an unstable 
nitrenium ion that attacks and forms adducts with guanine bases of DNA 
(Crosbie et al., 2000; Rindgen et al., 1995; Zhao et al., 1994). The DNA 
adducts can eventually lead to mutations. Indeed, in a variety of bacterial and 
mammalian systems PhIP was demonstrated to be a DNA damaging and 
mutagenic agent (Felton and Knize, 1991) (Boobis et al., 1996; Yadollahi-
Farsani et al., 1996),(Boyce et al., 2004; Boyce, 2014). The DNA-damaging 
and mutagenic properties of PhIP are therefore one mechanism by which the 
chemical can cause cancer. Independently from its DNA damaging activity, 
work in our laboratory (Gooderham et al., 2002; Lauber et al., 2004; Lauber 
and Gooderham, 2007, 2011) and by others (Bennion et al., 2005; Okudaira 
et al., 2013) identified PhIP as a potent stimulator of oestrogen receptor alpha 
(ERα), but not oestrogen receptor beta (ERβ). Oestrogen induces multiple 
important biological responses in exposed breast cancer cells and is an 
established risk factor for breast cancer (Ali and Coombes, 2002). The ability 
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of PhIP to activate ERα therefore represents an alternative, epigenetic 
mechanism, through which PhIP may drive breast carcinogenesis. However, 
two studies have questioned whether PhIP can indeed exert oestrogen 
hormone-like effects (Evans et al., 2010; Immonen et al., 2009) and therefore 
the ability of PhIP to act as a xenoestrogen is controversial.   
 
MicroRNAs (miRNAs) are a class of non-coding genes that repress post-
transcriptionally their target genes and are known to regulate cellular 
phenotypes such as proliferation, differentiation, apoptosis, and senescence. 
Dysregulation of miRNA has been implicated in various human diseases, 
including cancer (Mendell and Olson, 2012) and occurs following treatment 
with carcinogenic chemicals (Koufaris et al., 2012). A number of studies have 
reported that oestrogenic treatments result in altered miRNA expression in 
breast cancer cell lines (Klinge, 2012). Oestrogen regulates its target miRNA 
by diverse mechanisms, including the direct binding to oestrogen response 
element (ERE) in the promoters and enhancers of miRNA (Cicatiello et al., 
2010), by affecting biogenesis and processing of miRNA (Paris et al., 2012)  
or indirectly through the action of its target genes (Castellano et al., 2009). 
Functional studies have linked oestrogen-induced deregulation of miRNA with 
phenotypic changes that contribute to breast carcinogenesis (Castellano et 
al., 2009; Chu et al., 2014; Pinho et al., 2013).  Consequently, it is possible 
that aberrant miRNA expression induced by activation of ERα by PhIP could 
be an important factor in the carcinogenesis induced by the chemical. 
However, it should be noted that PhIP has also been reported to affect cellular 
pathways by mechanisms that are independent of ERα (Creton et al., 2007).  
 
To date no published studies have investigated the effects of PhIP exposure 
on the expression of miRNA in mammary cells. In this study we examined the 
effects of exposure to this potent mammary carcinogen on global miRNA 
expression in the oestrogen responsive and ER expressing MCF-7 breast 
cancer cell line. PhIP exposure induces rapid changes in target genes and 
pathways (Lauber et al., 2004) therefore we chose to look at acute (4-24 h) 
time points. Although several studies have examined the effects of E2 on the 
expression of miRNA, the reported effects are inconsistent (Klinge, 2012). 
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The inter-study variability is probably due to differences in time and dose of 
treatment, as well as the chosen cell culture conditions. Therefore, in order to 
investigate the degree to which the PhIP-induced alterations were associated 
with the oestrogen receptor, we also performed parallel treatments with 17-β-
estradiol (E2). Our findings demonstrate that PhIP exposure leads to altered 
expression of miRNA that has a strong similarity to alterations induced by 
exposure to E2 and indicate that deregulation of miRNA could be an important 
epigenetic mechanism contributing to the carcinogenic properties of the 
chemical. 
 
 
Material & Methods 
Cell culture 
 
The MCF-7 cell line used here was obtained from the European Collection of 
Cell Cultures. The cells were routinely maintained in minimal essential media 
supplemented with non-essential amino acids (MEM, Invitrogen), 10% FBS 
(Invitrogen), 2 mM L-glutamine (Invitrogen), and 100 IU/ml penicillin/100g/ml 
streptomycin (Invitrogen) in an incubator maintained at 5% CO2 and 37C. 
MCF-7 cells were cultured in phenol red-free MEM supplemented with 10% 
dextran coated charcoal stripped serum (DCCSS), 2 mM L-glutamine, and 
100 IU/ml penicillin/100g/ml streptomycin. To prepare the serum DCCSS 
dextran-coated charcoal (Sigma-Aldrich) was first added to FBS and left to stir 
overnight at 4ºC. The solution was then centrifuged at 1000 rpm for 20 
minutes at 4ºC, followed by decanting of FBS. The whole process was 
repeated twice. Finally the DCCSS was centrifuged for 30 minutes at 
3000rpm and filtered twice (0.2 μM filter). Dilutions of PhIP (Toronto Research 
chemicals) and E2 (Sigma-Aldrich) in absolute ethanol were added to each 
well at the appropriate dosage, with the final ethanol concentration set at 1%. 
For control cells the media was supplemented with absolute ethanol (final 
concentration 1%). All experiments were performed in triplicate. 
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E-Screen 
 
An E-SCREEN assay was performed following the method of Soto et al. (Soto 
et al., 1994), with modifications. Cells were seeded into 6-well plates at a 
density of 2.5 x 105 cells/well in DCSS supplemented media. The following 
day the media in the wells was replaced with DCSS media containing the 
tested compounds or ethanol vehicle. The treated cells were harvested after 
24, 48 and 72 hours and cell counts were performed using a Neubauer 
haemocytometer and trypan blue stain (Sigma-Aldrich).  
 
RNA extraction 
 
Total RNA was extracted from cells using Trizol (Invitrogen), following the 
manufacturer’s instructions. A Nanodrop ND-1000 was used to quantify the 
extracted RNA and evaluate the purity of the RNA solution by determining the 
260:280 and 260:230 ratios. The integrity of the isolated RNA was evaluated 
using the RNA 6000 Nano kit (Agilent) analysed on an Agilent Bioanalyser 
2100 (Agilent). RNA was used for subsequent analysis only if it had an RNA 
integrity number greater than eight and a 260:280 ratio greater than 2.0. 
 
 
MiRNA microarrays 
 
For the microarray experiments MCF-7 cells were treated as described 
previously (Lauber et al., 2004) with 10-7 M PhIP, 10-8 M E2 or ethanol vehicle 
for 4, 8, 12 or 24 hours. At each timepoint total RNA was collected. The RNA 
was dephosphorylated by incubation with Calf Intestine Alkaline Phosphatase 
(CIP) enzyme and and denatured by the addition of 100% dimethyl sulphoxide 
(DMSO). T4 RNA ligase was then used to ligate Cyanine 3-pCp onto RNA 
from cells kept in control media and Cyanine 5-pCp onto RNA extracted from 
cells treated with either PhIP or E2. The labelled RNA was subsequently 
isolated with the use of Micro Bio-Spin columns (Bio-Rad). Total RNA was 
labelled using the miRNA Complete Labeling and Hyb Kit (Cy3 and CY5, 
Agilent). The same kit was used to hybridise the labelled RNA onto Human 
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miRNA microarray kit V2 (Agilent). After washing, the slides were viewed 
using an Agilent scanner (G2505B), and the data were collected using Agilent 
Feature Extraction v.10.1 software.  
Normalisation, processing, and analysis of miRNA microarray data 
The raw microarray data files were processed and normalised in BRB-Array 
tools. Probes were excluded from the analysis if the intensity in the green or 
red channel (Cy3 and Cy5 respectively) was below 100 in both channels or if 
the probe size was below 10. Probe signal was averaged for replicate probes 
on each slide. The data were then log2 transformed and lowess smooth 
normalised. MiRNA were removed from further analysis if they were not 
flagged as present in at least 50% of samples. Due to the fact that RNA 
samples from PhIP and E2 treated cells were hybridized on the same arrays 
as RNA from vehicle treated cells, only relative miRNA expression levels were 
determined. In order to analyze the dataset through a statistically sound filter 
that accounted for the magnitude of expression change as well as for 
confidence intervals, miRNAs responsive to PhIP and E2 treatments were 
deemed those displaying greater than 1.5 fold upregulation or downregulation 
and at least two standard deviations distant, compared to vehicle treated 
cells. Hierarchical clustering analysis of microarray samples was performed 
using the clustering function in BRB-ArrayTools using average linkage and 
correlation centered 
Quantitative Reverse Transcription PCR (qRT-PCR) 
Total RNA was reverse transcribed to cDNA using MMVL reverse 
transcriptase (Promega) and oligo dT primer (Sigma-Aldrich). To quantify 
selected miRNA by qRT-PCR the Platinum SYBR Green qPCR SuperMix-
UDG (Invitrogen) was used with Universal qPCR primer and miRNA specific 
primers at a concentration of 200 nM. The PCR was performed in an ABI 
7500 Real-Time PCR instrument (Applied Biosystems). The levels of the 
miRNA were determined by the ΔΔCT method using U6 as the internal 
reference. 
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Statistical Analysis 
Statistical analysis was performed using ANOVA with Tukey or Dunnet’s post-
test. 
 
 
Results 
E-Screen for 17-β-estradiol and PhIP 
 
The E-screen is a well-established assay for oestrogenic activity (Soto et al., 
1994). The basis of this assay is that MCF-7 cells are growth-inhibited in 
media containing DCCSS human serum and will only proliferate in the 
presence of E2 or chemicals with oestrogenic properties. In our previous 
study, treatment with PhIP resulted in a concentration dependent increase in 
MCF-7 proliferation (Lauber et al., 2004). Here we examined doses of PhIP 
from 10-11 to 10-6 Molar and multiple time-points (24, 48, and 72 hours). Under 
these experimental conditions PhIP induced non-monotonic proliferative 
responses in MCF-7 cells at all time-points (Fig.1A). No significant 
proliferative response was observed at any time-point in response to 
treatment with the highest PhIP dose tested here, 10-6 M. As expected, a non-
monotonic proliferative response was also observed for E2 under these 
conditions (Fig.1B).  
 
Effect of E2 and PhIP on miRNA expression in MCF-7 cells 
 
The doses of E2 (10-8 M) and PhIP (10-7 M) which resulted in the strongest 
proliferative response in MCF-7 cells in the E-SCREEN (Fig.1) were chosen 
for further study. MiRNA microarrays were used to profile the expression of 
miRNA in MCF-7 cells treated with the chemicals or with vehicle control for 4, 
8, 12, and 24 hours. After processing of the samples as described in Materials 
& Methods, 723 mature miRNA were detected in the microarray data. Box plot 
analysis demonstrated comparable distributions for the microarray samples 
(Fig.2A), supporting the robust nature of the datasets.  
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Hierarchical clustering analysis of the microarray samples revealed a clear 
demarcation of miRNA profiles for MCF-7 cells treated with PhIP or E2 
(Fig.2B).  Those miRNA displaying a greater than two standard deviations 
and a 1.5 fold upregulation or downregulation compared to vehicle treated 
cells were designated as responsive to chemical treatment. Using this criteria 
35 miRNA out of the 723 detected were classified as responsive to E2 and 24 
to PhIP at one or more of the examined timepoints (Tables 1-2).  Examination 
of the updated version miRBase database (version 20) showed that miR-923 
and miR-801 have been wrongly classified as miRNA (the former redefined as 
a fragment of 28s rRNA while the latter as a fragment of U11 spliceosomal 
RNA). Consequently, these were removed from further analysis. To verify the 
microarray results by an independent method we quantified by qRT-PCT the 
two miRNA (miR-663 and miR-638) that showed the largest magnitude of 
response in PhIP vs. vehicle treated cells according to the microarray data. 
This analysis confirmed a high degree of concordance between microarray 
and qRT-PCR for these miRNA (Fig.2C). 
 
Importantly, there was a significant overlap in the miRNA deregulated by PhIP 
and E2 at each time-point (Fig.3A-D), with 15 out of 24 miRNA responsive to 
PhIP also being responsive to E2. Overall, despite the presence of some 
variability, the direction and magnitude of response for the majority of the 
miRNA were consistent across the four examined time-points (Tables 1-2 and 
Fig.4), indicating the role of miRNA deregulation in the observed proliferative 
response to PhIP. A number of the miRNA affected by PhIP have been 
previously reported to be regulated by oestrogen including miR-21 
(Wickramasinghe et al., 2009), miR-16 (Yu et al., 2012), miR-200c 
(Manavalan et al., 2013), miR106b (Castellano et al., 2009), miR-26a and 
miR-24 (Maillot et al., 2009), further supporting the notion that PhIP has 
estrogenic-like activity. 
 
 
 
 10 
Discussion 
 
Expanding on our previous work we showed that PhIP induced time and 
dose-dependent increased proliferation of MCF-7 cells (Fig.1), confirming the 
ability of the chemical to act as a xenoestrogen. By using a wider-range of 
concentrations we also showed for the first time that proliferation in the 
ESCREEN in response to PhIP stimulation is of a non-monotonic nature 
(Fig.1A). A similar non-monotonic response was also observed in response to 
E2 treatment (Fig.1B) in the same MCF-7 cell line. Importantly, the non-
monotonic response to both treatments was observed at all examined time-
points, supporting the validity of this response in our experimental setup.  
Non-monotonic responses to hormones and endocrine–disrupting chemicals, 
including E2, are a matter of ongoing debate in regards to their validity and 
relevance (Vandenberg et al., 2012) (Rhomberg and Goodman, 2012). In this 
study the mechanistic basis for the observed non-monotonic response to the 
two chemicals was not explored, but could include activation of distinct ERα-
independent signalling pathways as well as negative feedback loops that 
could be linked with the notable decrease of the proliferative response at the 
highest dose for both treatments. It is therefore probable that the observed 
non-monotonic responses to PhIP and E2 share a similar mechanism, based 
on the shape of the dose-response curves.  
 
Activity of ERα is known to affect miRNA by diverse mechanisms that include 
direct binding to promoters and enhancer elements to activate transcription 
and by affecting miRNA processing (Klinge, 2012). It was shown in this study 
for the first time that PhIP exposure elicits wide-spread effects on the 
miRNAome of a breast cancer cell line (Table 1). Importantly, miRNA that 
were responsive to PhIP were also affected by E2 treatment (for example 
miRs-21, -663, -638, -330-5p, -518C*, -574-5p, 923) (Table 2; Fig.3 and 4). 
The similar effects of PhIP and E2 treatments on miRNA expression that are 
determined here (Tables 1-2) provide grounds for PhIP driving miRNA 
deregulation through the activation of ERα. For at least one of the commonly 
affected miRNA, miR-21, it has been reported that it is transcriptionally 
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regulated by ERα (Wickramasinghe et al., 2009). However, in the absence of 
additional experimental data it is not possible to differentiate between miRNA 
expression changes that are directly mediated by ERα and those that stem 
from secondary events. Discrimination between direct and indirect miRNA 
regulation by the activated ERα would require additional experiments such as 
chromatic immunoprecipitation. It was also observed that the majority of the 
miRNA affected by the treatments displayed reduced expression (Tables 1-2). 
A more wide-spread repression of miRNA rather than upregulation following 
E2 treatment in breast cancer cells is consistent with some studies (Maillot et 
al., 2009) (Yu and Snyderwine, 2002), but not others (Klinge, 2012). It has 
been suggested that the repression of miRNA by E2 is involved in the 
increased proliferation of mammary cells when stimulated with the hormone 
(Maillot et al., 2009; Yu et al., 2012).  
 
At the same time, there were also differences in the miRNA profiles of MCF-7 
cells treated with PhIP and E2, as evidenced by clustering of samples and 
miRNA affected by only one treatment (Fig.2B; Fig.3). A potential difference 
between PhIP and E2 is the DNA adduct forming properties of the former. In 
vivo the genotoxicity of PhIP is dependent on metabolism by the CYP1 
enzymes. The MCF-7 cell line possesses active CYP1A enzymes that can 
metabolise PhIP to its DNA-reactive form.  However, the PhIP doses used in 
this study are much lower than the micromolar levels that are required for 
such genotoxic activity. It is also the case that the miRNA affected by PhIP in 
this study are different to those that have been reported to be affected by 
DNA damage signalling e.g. the induction of the miR-34 family by p53 (He et 
al., 2007). In fact, our study shows a stronger induction for miR-34b for E2 
treated MCF-7 cells after 24 hours compared to PhIP treated cells, that could 
be a result of the upregulation of p53 and Mdm2 by E2 treatment (Qin et al., 
2002). It is likely that distinct effects of PhIP on miRNA expression are either 
due to differential degrees of ERα activation or ER-independent effects of the 
two compounds, rather than the DNA-adduct forming effects of PhIP.  
  
Given that miRNA deregulation can drive breast carcinogenesis (Shimono et 
al., 2009; Song et al., 2013) it is plausible that the ability of PhIP to deregulate 
 12 
miRNA through activation of ERα could be an important mechanism in PhIP-
mediated carcinogenesis and be implicated in the phenotypic consequences 
of exposure to the chemical. PhIP treatment has been reported to upregulate 
the anti-apoptotic BCL-2 in the mammary gland of rats (Venugopal et al., 
1999). Interestingly, BCL-2 expression has been shown to be repressed in 
MCF-7 cells by miR-21 (Wickramasinghe et al., 2009), miR-16 (Yu et al., 
2012),  and miR-24 (Srivastava et al., 2011), all of which were downregulated 
by PhIP in this study.  PhIP has also been shown to affect metastatic potential 
in vitro (Lauber and Gooderham, 2011). In this study PhIP repressed miR-
200c/141, miRNA that are master regulators of invasiveness and metastasis 
(Burk et al., 2008). H-Ras, an oncogene that is mutated in PhIP-induced 
breast cancer (Yu and Snyderwine, 2002) is also targeted by miR-663 (Yang 
et al., 2013), one of the most strongly suppressed miRNA identified in this 
study. However, whether the miRNA deregulation identified in this study can 
be extrapolated to in vivo mammary tissue in exposed animals or humans is 
not clear. Our previous reports show that the effects of xenobiotics on miRNA 
profiles in vivo are highly dependent on the dose and time of exposure 
(Koufaris et al., 2013). Additionally, oestrogenic effects on miRNA expression 
are reported to be highly variable according to cell culture conditions (Klinge, 
2012).  
 
Two published studies have questioned the ability of PhIP to induce 
oestrogenic responses in breast cancer cells (Evans et al., 2010; Immonen et 
al., 2009) however, a number of observations are at variance with their 
conclusions. Computational receptor binding studies predict that PhIP fits the 
ERα (Bennion et al., 2005; Nettles et al., 2008). Oestrogenicity of PhIP has 
been reported in a number of different in vitro assays such as in COS-1 cells 
transiently transfected with ERα, activation of luciferase reporter-gene in 
MELN cells, and induction of proliferation in MCF-7 cells (Lauber et al., 2004; 
Lauber and Gooderham, 2007). The ability of PhIP to induce oestrogenic-
dependent responses is also supported by the work of independent labs 
(Bennion et al., 2005; Okudaira et al., 2013). Importantly, blocking oestrogenic 
signalling disrupts the ability of PhIP to induce phenotypic responses in 
exposed cells (Lauber et al., 2004; Lauber and Gooderham, 2007, 2011; 
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Okudaira et al., 2013). Consequently, we consider it highly unlikely that the 
ability of PhIP to induce oestrogenic-dependent responses identified by 
ourselves and others is artifactual. It is also important to note that the two 
contradictory studies did not attempt to replicate the original findings and 
varied in experimental conditions such as cell type, treatment doses, 
exposure times, and seeding densities. A further complication is that a variety 
of MCF-7 sublines exist which differ in their sensitivity to oestrogenic 
treatments (Villalobos et al., 1995). The non-monotonic oestrogen response to 
PhIP (Fig.1) further emphasises the importance of dose and temporal 
considerations.  
 
A recent study employing a specific assay for PhIP-DNA adducts suggested 
that the incidence of adduct formation in mammary tissue in humans is 
relatively low (Gu et al., 2012). Yet the tissue specificity of the carcinogenic 
effects of PhIP involves selectivity for the breast, and suggests that a 
predominantly genotoxic mechanism of action is unlikely. This is supported by 
the fact that the reported levels of PhIP exposure anticipated to occur in 
humans are likely to be below those shown to induce mutagenesis (Lauber et 
al., 2004; Lynch et al., 1992), although they are within the range of exposures 
shown to give rise to measurable PhIP-DNA adducts (Turteltaub et al., 1999). 
Doses of PhIP that are estimated to be within physiologically relevant levels 
have been reported to activate ERα and induce multiple effects that could 
contribute to carcinogenesis including increased proliferation, prolactin 
secretion, invasiveness (Lauber et al., 2004; Lauber and Gooderham, 2007, 
2011), and long interspersed element-1 (L1) mediated genomic instability 
(Okudaira et al., 2013). Whilst the former studies investigating the hormone-
like properties of PhIP were based on cell line models (Lauber et al., 2004; 
Lauber and Gooderham, 2007, 2011), importantly, Okudaira et al.,(Okudaira 
et al., 2013) used transgenic mice to detect in vivo ERα-dependent genomic 
instability caused by PhIP exposure, supporting the biological relevance of 
this mechanism. The data generated in the present study support these 
previous reports and demonstrate that in MCF-7 breast cancer cells PhIP 
exposure can also drive the deregulation of miRNA expression (Fig.2-3). 
Thus this work adds further mechanistic support to the hypothesis that life-
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long exposure to low levels of PhIP could increase the incidence of breast 
cancer through oestrogenic mechanisms. 
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Table 1 miRNA responsive to PhIP (10-7M) treatment of MCF-7 cells 
 
miRNA 4 hours 8 hours 12 hours 24 hours 
miR-1 0.8±0.05 1.0±0.16 0.6±0.07 1.1±0.52 
miR-106b 0.8±0.02 0.7±0.04 0.8±0.07 0.6±0.09 
miR-141 0.8±0.09 0.8±0.05 0.9±0.10 0.6±0.13 
miR-16 0.8±0.10 0.6±0.05 0.7±0.07 0.6±0.16 
miR-200c 0.8±0.14 0.7±0.7 0.8±0.11 0.6±0.18 
miR-21 0.7±0.12 0.6±0.05 0.7±0.05 0.5±0.13 
miR-24 0.8±0.10 0.7±0.05 0.8±0.08 0.6±0.16 
miR-26a 0.8±0.10 0.7±0.05 0.8±0.08 0.6±0.16 
miR-30d 0.8±0.12 0.7±0.03 0.8±0.09 0.6±0.14 
miR-330-5p 0.5±0.01 0.6±0.05 0.6±0.01 0.6±0.03 
miR-494 1.6±0.18 1.5±0.10 2.0±0.58 1.4±0.25 
miR-518c* 0.6±0.05 0.6±0.04 0.7±0.08 0.6±0.06 
miR-574-3p 1.3±0.15 1.4±0.10 1.2±0.23 1.7±0.20 
miR-574-5p 1.7±0.14 1.7±0.29 1.6±0.21 2.0±0.33 
miR-612 0.6±0.01 0.7±0.02 0.7±0.05 0.8±0.09 
miR-615-5p 0.6±0.04 0.6±0.01 0.7±0.05 0.6±0.01 
miR-638 0.5±0.04 0.5±0.03 0.8±0.29 0.6±0.03 
miR-654-5p 0.6±0.03 0.7±0.03 0.7±0.05 0.7±0.05 
miR-663 0.4±0.01 0.5±0.04 0.6±0.15 0.5±0.03 
miR-801a 0.6±0.03 0.6±0.03 0.6±0.01 0.6±0.03 
miR-923a 2.2±0.09 2.0±0.08 3.1±0.82 2.5±0.40 
 
The miRNA listed here are those with a fold change at least 1.5-fold change and two 
standard deviations from vehicle-treated cells in one or more time-points. Mean fold 
change in PhIP treated cells compared to vehicle treated cells and standard deviation 
are shown. Underlined are data fulfilling criteria. 
aMiRBase (version 20) indicates that these are wrongly classified as miRs.  
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 Table 2 miRNA responsive to E2 (10-8M) treatment of MCF-7 cells. 
miRNA 4 hours 8 hours 12 hours 24 hours 
miR-1226* 0.6±0.01 0.7±0.02 0.7±0.13 0.7±0.02 
miR-1228* 0.6±0.04 0.6±0.05 1.1±0.71 0.6±0.07 
miR-1229 1.4±0.2 1.3±0.13 1.1±0.25 1.7±0.26 
miR-1233 1.4±0.21 1.3±0.15 1.2±0.21 1.6±0.29 
miR-141 0.9±0.09 0.9±0.02 0.9±0.09 0.6±0.16 
miR-149* 0.7±0.07 0.6±0.03 1.2±0.80 0.6±0.6 
miR-150* 0.6±0.02 0.6±0.01 0.6±0.10 0.6±0.16 
miR-197 1.5±0.14 1.4±0.10 1.1±0.21 1.6±0.14 
miR-21 0.7±0.10 0.7±0.02 0.7±0.06 0.6±0.14 
miR-330-5p 0.5±0.01 0.6±0.05 0.6±0.04 0.5±0.02 
miR-34b 1.4±0.06 1.4±0.06 1.2±0.23 1.6±0.14 
miR-518c* 0.6±0.05 0.6±0.04 0.6±0.06 0.6±0.06 
miR-574-3p 1.4±0.2 1.3±0.17 1.3±0.18 1.7±0.23 
miR-574-5p 1.7±0.16 1.6±0.29 1.5±0.25 2.0±0.20 
miR-585 0.6±0.03 0.7±0.04 0.9±0.25 0.6±0.05 
miR-595 1.4±0.10 1.2±0.12 1.2±0.20 1.6±0.29 
miR-612 0.6±0.02 0.7±0.01 0.7±0.05 0.7±0.04 
miR-615-5p 0.6±0.03 0.7±0.04 0.6±0.03 0.6±0.02 
miR-638 0.4±0.04 0.4±0.03 0.7±0.34 0.3±0.03 
miR-654-5p 0.6±0.02 0.7±0.03 0.7±0.03 0.6±0.03 
miR-663 0.3±0.01 0.4±0.04 0.4±0.17 0.3±0.03 
miR-671-5p 0.7±0.03 0.7±0.01 0.8±0.09 0.6±0.05 
miR-766 1.7±0.55 1.4±0.37 1.4±0.47 2.3±0.61 
miR-801a 0.7±0.03 0.6±0.03 0.6±0.07 0.7±0.05 
miR-885-5p 1.3±0.10 1.3±0.05 1.2±0.31 1.6±0.26 
miR-923a 2.2±0.09 2.0±0.08 2.8±0.98 2.0±0.19 
miR-92b* 0.5±0.04 0.5±0.04 0.9±0.65 0.5±0.03 
 
The miRNA listed here are those with a fold change at least 1.5-fold change and two 
standard deviations from vehicle-treated cells in one or more time-points. Mean fold 
change in E2 treated cells compared to vehicle treated cells and standard deviation 
are shown. Underlined are data fulfilling criteria.  
aMiRBase (version 20) indicates that these are wrongly classified as miRs. 
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Figure Legends 
 
Fig.1 Effect of PhIP and E2 on proliferation of MCF-7 cells (A) PhIP-treated 
cells compared to negative control; (B) E2-treated cells compared to negative 
control. Values are mean with standard deviation * p<0.05 ** p<0.01; n=3 
(ANOVA) 
 
Fig.2 Verification of miRNA microarray data and clustering analysis (A) Each 
box plot on the x-axis represents a treatment sample and data points are 
individual microRNAs; (B) Hierarchical clustering analysis of microarray 
samples from PhIP (P, 10-7M) and E2 (E, 10-8M) treated MCF-7 cells; (C) 
Comparison of qRT-PCR and microarray data for miR-663; (D) Comparison of 
qRT-PCR and microarray data for miR-638. Pearson’s correlation (r) is 
shown. 
 
Fig.3 Comparison of effects of PhIP (10-7M) and E2 (10-8M) treatment on 
miRNA expression in MCF-7 cell line at different time-points (A) after 4 hours; 
(B) after 8 hours; (C) after 12 hours; (D) after 24 hours. Each oval represents 
a time-point of treatment. MiRNA responsive to both E2 and PhIP are shown 
in the intersection region of ovals. MiRNA with downregulated expression are 
depicted as underlined. 
 
Fig.4 Heatmap displaying averaged expression of miRNA responsive to E2 or 
PhIP with time of treatment. MiRNA with increased expression compared to 
vehicle treated cells are shown in red, those with decreased expression are 
shown in green, black colour indicates no change in expression compared to 
control. 
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